What if you invested in Moderna in 2023?
MRNA · Healthcare · Data through 2026-06-01
If you invested $1,000 in Moderna in 2023
The same $1,000 in the S&P 500 would be worth $1,916(+91.6%)
The S&P 500 returned $1,916 on the same $1,000. S&P 500 outperformed by $1,519.
Try a different start date
Pick any month and year to see what Moderna would be worth.
Compare Moderna to another stock
See how Moderna stacks up since 2023, head to head.
What if Moderna keeps this up?
Project forward with custom growth rates. See 5-30 year scenarios.
Growth of $1,000
Moderna vs. S&P 500 vs. US Dollar, 2023 to present
Year-by-Year Returns
$1,000 invested in Moderna starting January 2023
| Year | Price | Value | Annual |
|---|---|---|---|
| 2023 | $176.06 | $1,000 | - |
| 2024 | $101.05 | $574 | -42.6% |
| 2025 | $39.42 | $224 | -61% |
| 2026 | $44.07 | $250 | +11.8% |
What this return means
Moderna (MRNA) is one of the losers in this dataset. That stake is worth $398 as of 2026-06-01, a -60.2% move that left you with less than you started with after 3.6 years.
That averages out to -22.7% a year, meaning the position shrank in compound terms across the 3.6-year window. By comparison the S&P 500 returned about $1,916 on the same stake, edging out Moderna by close to $1,519. The index compounded at about 19.9% a year, a reminder that a single stock can lag a basket of them.
Getting here meant sitting through real volatility. The best single year was 2024 at -42.6%, and the worst was 2025 at -61.0%. At its lowest point the position was down about 78% from an earlier high. These figures use split-adjusted closing prices and exclude dividends, taxes, trading fees, and inflation, so a real after-tax result would differ.
This is historical math, not financial advice. Past performance does not guarantee future results.
What if you invested $100 a month instead?
Most people do not drop a lump sum in on day one. They add a fixed amount every month. Putting $100 into Moderna at the close of every month from January 2023 through June 2026 means 42 buys and $4,200 contributed over about 3.5 years.
$100/month, dollar-cost averaged
$5,645
+34.4% on $4,200 in
Same $4,200, all in at the start
$1,671
-60.2% on $4,200 in
Spreading the buys out beat going all in at the start by $3,974. That happens when the price spent time below where it began, so averaging in caught the cheaper months. Averaging in also meant an average buy price of $52.10 per share across the whole stretch, so the monthly buyer never had to time a single low. Neither number counts dividends, taxes, or trading costs.
Illustrative fixed $100/month example, not a recommendation. Figures are computed from MRNA split-adjusted monthly closes through June 2026. Past performance does not guarantee future results.
Moderna at different times
See how the start year changes the outcome
Featured matchup
See this investment against its closest market rivals
More Healthcare investments
Compare returns across the sector
Related reading
Deep dives and analysis
Numbers worth sharing
Occasional data drops when something interesting surfaces. No schedule, just signal.
For informational and educational purposes only. Not financial advice. Past performance does not guarantee future results. All calculations are based on split-adjusted closing prices from Yahoo Finance and do not account for dividends, taxes, or trading fees. See our methodology and full disclaimer.